Referred Tests
Leading
the way
Testing developed
by neurologists, for neurologists
Neurology testing is rapidly evolving, with increasing numbers of clinically relevant biomarkers discovered each year. Our laboratory collaborates closely with the practice and is designed to offer the most complex, clinically validated testing. Our disease experts support health care professionals in test selection and results interpretation to ensure proper test utilization and the highest quality of care. These physicians are committed to research and discovery to pave the way for the future of neurology testing.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly neurology newsletter.
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
400+
laboratory tests developed for our specialized neurology test menu
169
neurologists on staff at Mayo Clinic
19
testing laboratories performing
neurology testing
24/7
support from Mayo Clinic physicians and scientists
Advancing the
science
Novel biomarker discoveries occur at a rapid pace, and we are at the forefront of research that integrates these findings into our testing. We were the first laboratory to develop disease-specific evaluations, and our patient care experience gives us the expertise to develop tests that deliver clinically relevant answers.
The largest neurology-specific test menu
Our highly specialized test menu provides answers for everything from the simplest to the most complex cases — and much of this testing is not available anywhere else.
Access to Mayo Clinic expertise
Our laboratories are led by clinical neurologists who have extensive experience in using testing to guide and directly impact patient care. These experts interpret each evaluation, providing clinically actionable answers, not just results.
Advancing the search for KLHL11 protein biomarkers
The groundbreaking discovery that testicular cancer-associated paraneoplastic encephalitis is caused by KLHL11 autoantibodies — by a team of researchers that included Mayo Clinic scientists — paved the way for development of the assay. The innovative test first screens patients for KLHL11 proteins through a mechanized, cell-based assay that utilizes cutting-edge, slide-scanner technology, then employs tissue immunofluorescence to confirm presence of the protein, which exudes a unique "sparkles" pattern.
The latest
PACE / State of CA / State of FL
This “Specialty Testing” webinar will discuss the collaborative effort which led to the discovery of Kelch like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity associated testicular germ cell tumor.
In this month’s “Hot Topic,” Sean Pittock, M.D., explains Neuromyelitis Optica Spectrum Disorder (NMOSD) and the critical importance of a sensitive and specific AQP4-IgG laboratory test for early diagnosis and treatment.
Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated paraneoplastic encephalitis.
Mayo Clinic Laboratories has launched a first-in-the-U.S. autoimmune test of the Kelchlike protein 11 antibody, or KLHL11, which is used to detect autoimmune disease associated with testicular cancer.
In this month’s “Hot Topic,” Andrew McKeon, M.B., B.Ch., M.D., reviews the use of neurological phenotype-based evaluations, the move away from the paraneoplastic evaluation, and upcoming changes to test profiles.